abstract |
The present invention relates to new condensed pyrrolocarbazoles or isoindolones, including pharmaceutical compositions having activity against trk kinase, platelet derived growth factor receptor kinase (PDGFR), vascular endothelial growth factor receptor kinase (VEGFR) kinase, NGF-stimulated trk phosphorylation or on trophic factor of cells. |